A Randomised Controlled Trial of Intravenous Zoledronic Acid in Malignant Pleural Disease: A Proof of Principle Pilot Study

作者：Clive Amelia O; Hooper Clare E; Edey Anthony J; Morley Anna J; Zahan Evans Natalie; Hall David; Lyburn Iain; White Paul; Braybrooke Jeremy P; Sequeiros Iara; Lyen Stephen M; Milton Tim; Kahan Brennan C; Maskell Nick A^*

来源：PLos One, 2015, 10(3): e0118569.

DOI：10.1371/journal.pone.0118569

Introduction
Animal studies have shown Zoledronic Acid (ZA) may diminish pleural fluid accumulation and tumour bulk in malignant pleural disease (MPD). We performed a pilot study to evaluate its effects in humans.
Methods
We undertook a single centre, double-blind, placebo-controlled trial in adults with MPD. Patients were randomised (1: 1) to receive 2 doses of intravenous ZA or placebo, 3 weeks apart and were followed-up for 6 weeks. The co-primary outcomes were change in Visual Analogue Scale (VAS) score measured breathlessness during trial follow-up and change in the initial area under the curve (iAUC) on thoracic Dynamic Contrast Enhanced Magnetic Resonance Imaging (DCE-MRI) from randomisation to week 5. Multiple secondary end-points were also evaluated.
Results
Between January 2010 and May 2013, 30 patients were enrolled, 24 randomised and 4 withdrew after randomisation (1 withdrew consent; 3 had a clinical decline). At baseline, the ZA group were more breathless, had more advanced disease on radiology and worse quality of life than the placebo group. There was no significant difference between the groups with regards change in breathlessness (Adjusted mean difference (AMD) 4.16 (95% CI -4.7 to 13.0)) or change in DCE-MRI iAUC (AMD -15.4 (95% CI -58.1 to 27.3). Two of nine (22%) in the ZA arm had a >10% improvement by modified RECIST (vs 0/11 who received placebo). There was no significant difference in quality of life measured by the QLQ-C30 score (global QOL: AMD -4.1 (-13.0 to 4.9)), side effects or serious adverse event rates.
Conclusions
This is the first human study to evaluate ZA in MPD. The study is limited by small numbers and imbalanced baseline characteristics. Although no convincing treatment effect was identified, potential benefits for specific subgroups of patients cannot be excluded. This study provides important information regarding the feasibility of future trials to evaluate the effects of ZA further.

• 出版日期2015-3-17